Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964756 · ClinicalTrials.gov registry record · Phase 1
A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00964756 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 11 participants.
The verdict
NCT00964756, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
In spite of surgical and chemotherapeutic advances, long term survival for advanced and recurrent gynecologic cancers remains dismal and no curative treatment for recurrent disease exists. Novel treatment strategies are needed. This is a study to determine the maximally tolerated dose of and toxicities associated with intraperitoneal delivery of an infectivity enhanced adenovirus that expresses a suicide gene and an gene that allows imaging of gene transfer. This vector will be given in combination with intravenous ganciclovir in patients with recurrent ovarian and other gynecological cancers.
Interventions
- DRUG Ganciclovir (GCV)
- GENETIC Ad5.SSTR/TK.RGD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00964756
The ClinicalTrials.gov registry entry for NCT00964756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ganciclovir (GCV) is the first listed.
NCT00964756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00964756 about?
NCT00964756 is a clinical study titled "A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers". In spite of surgical and chemotherapeutic advances, long term survival for advanced and recurrent gynecologic cancers remains dismal and no curative treatment for recurrent disease exists. Novel treatment strategies are needed. This is a study to determine the maximally tolerated dose of and toxicit...
What is the current status of trial NCT00964756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00964756?
The interventions under investigation include: Ganciclovir (GCV) (DRUG), Ad5.SSTR/TK.RGD (GENETIC).
Who is sponsoring clinical trial NCT00964756?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.